Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Clancy

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
American Journal of Respiratory and Critical Care Medicine|February 13, 2016
Cystic Fibrosis Transmembrane Conductance Regulator Function in Airway Smooth Muscle. A Novel Role in Cystic Fibrosis Airway ObstructionJohn P Clancy
Pediatric Pulmonology|October 6, 2018
Rapid therapeutic advances in CFTR modulator scienceJohn P Clancy
Science Translational Medicine|August 8, 2014
CFTR potentiators: not an open and shut caseJohn P Clancy
Therapeutic Advances in Respiratory Disease|September 6, 2013
Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidenceKavitha Kotha, John P Clancy
Future Microbiology|November 18, 2015
Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacinZarmina Ehsan, John P Clancy
American Journal of Respiratory and Critical Care Medicine|June 23, 2012
Personalized medicine in cystic fibrosis: dawning of a new eraJohn P Clancy, Manu Jain
Expert Opinion on Orphan Drugs|January 3, 2017
CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on IvacaftorElizabeth L Kramer, John P Clancy
Expert Opinion on Therapeutic Targets|November 24, 2017
TGFβ as a therapeutic target in cystic fibrosisElizabeth L Kramer, John P Clancy
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 25, 2009
Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in developmentSteven M Rowe, John P Clancy
Current Opinion in Pediatrics|November 14, 2006
Advances in cystic fibrosis therapiesSteven M Rowe, John P Clancy
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
American Journal of Respiratory and Critical Care Medicine|February 13, 2016
Cystic Fibrosis Transmembrane Conductance Regulator Function in Airway Smooth Muscle. A Novel Role in Cystic Fibrosis Airway ObstructionJohn P Clancy
Pediatric Pulmonology|October 6, 2018
Rapid therapeutic advances in CFTR modulator scienceJohn P Clancy
Science Translational Medicine|August 8, 2014
CFTR potentiators: not an open and shut caseJohn P Clancy
Therapeutic Advances in Respiratory Disease|September 6, 2013
Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidenceKavitha Kotha, John P Clancy
Future Microbiology|November 18, 2015
Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacinZarmina Ehsan, John P Clancy
American Journal of Respiratory and Critical Care Medicine|June 23, 2012
Personalized medicine in cystic fibrosis: dawning of a new eraJohn P Clancy, Manu Jain
Expert Opinion on Orphan Drugs|January 3, 2017
CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on IvacaftorElizabeth L Kramer, John P Clancy
Expert Opinion on Therapeutic Targets|November 24, 2017
TGFβ as a therapeutic target in cystic fibrosisElizabeth L Kramer, John P Clancy
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 25, 2009
Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in developmentSteven M Rowe, John P Clancy
Current Opinion in Pediatrics|November 14, 2006
Advances in cystic fibrosis therapiesSteven M Rowe, John P Clancy
Pageof 13